STOCK TITAN

Biocryst Pharmaceuticals Inc. - BCRX STOCK NEWS

Welcome to our dedicated news page for Biocryst Pharmaceuticals (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biocryst Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biocryst Pharmaceuticals's position in the market.

Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) granted stock options and restricted stock units to eight newly-hired employees. The options and RSUs total 48,700 and 34,000 shares, respectively, with an exercise price of $5.99 per share. Vesting occurs in four equal annual installments, subject to continued service, with each option having a 10-year term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.67%
Tags
none
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (BCRX) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
conferences
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announces publication of data from the open-label extension (OLE) of the APeX-2 trial of ORLADEYO for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older. Results show rapid and sustained reductions in HAE attacks and improved quality of life over 96 weeks of treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) granted 16 newly-hired employees stock options to purchase 74,500 shares and restricted stock units covering 51,050 shares. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $5.88 per share, vesting in four equal annual installments beginning on the one-year anniversary of the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.11%
Tags
none
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has received approval from ANMAT in Argentina for ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years of age or older. The partnership with Pint Pharma GmbH aims to bring ORLADEYO to patients in Latin America, marking a significant step in improving the management of HAE attacks in the region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (BCRX) will present at the 6th Annual Evercore ISI HealthCONx Conference on November 28th and the 35th Annual Piper Sandler Healthcare Conference on November 29th, 2023. The live audio webcasts and replays will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
conferences
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (BCRX) has received marketing authorization from the Spanish Ministry for Health for ORLADEYO® (berotralstat) for the prevention of recurrent hereditary angioedema attacks in HAE patients 12 years and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
none
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced new analyses of real-world use of ORLADEYO, leading to a reduction in monthly attack rates in patients with hereditary angioedema (HAE) who have normal C1-inhibitor (C1-INH) level and function. The data are being presented at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst's board of directors granted 11 newly-hired employees stock options to purchase 80,700 shares and restricted stock units (RSUs) covering 38,600 shares of BioCryst common stock. The options and RSUs were granted on October 31, 2023, with an exercise price of $5.49 per share, equal to the closing price on the grant date. They vest in four equal annual installments starting on the one-year anniversary of the grant date, subject to the new employee's continued service with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
none
Rhea-AI Summary
BioCryst Pharmaceuticals announces updates from its drug discovery process and additional therapies from its pipeline. They highlight BCX17725 for Netherton syndrome, a fusion protein for complex complement-mediated diseases, an oral C5 program for generalized myasthenia gravis, and avoralstat for diabetic macular edema. The company plans to begin clinical trials for these therapies in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.09%
Tags
clinical trial
Biocryst Pharmaceuticals Inc.

Nasdaq:BCRX

BCRX Rankings

BCRX Stock Data

1.06B
190.90M
1.22%
88.05%
14.11%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Durham

About BCRX

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.